Merck Advances Tulisokibart’s Clinical Reach: New Phase 2b Trials Target Three Immune Diseases

Merck has announced a significant expansion of its clinical development program for tulisokibart (MK-7240), an investigational monoclonal antibody targeting the inflammatory mediator TL1A. Reported by Drugs.com, in October 2025, the…

Continue Reading Merck Advances Tulisokibart’s Clinical Reach: New Phase 2b Trials Target Three Immune Diseases

Why Your Brain Might Be Hijacking Your Wakefulness: Understanding Hypersomnia and Narcolepsy

Excessive daytime sleepiness (EDS) is more than just feeling tired—it can be a debilitating symptom of two distinct neurological disorders: hypersomnia and narcolepsy. While both conditions share the hallmark of…

Continue Reading Why Your Brain Might Be Hijacking Your Wakefulness: Understanding Hypersomnia and Narcolepsy